Page 1 | Search Results | Blood | American Society of Hematology

1-20 of 41

Sort by

Sort Order Select

Journal Articles

Interim Analysis of a Phase II Study of the Glutaminase Inhibitor Telaglenastat (CB-839) in Combination with Azacitidine in Advanced Myelodysplastic Syndrome (MDS)

Veronica A Guerra, MD, Jan A. Burger, MD PhD, Gautam M. Borthakur, MD, Elias Jabbour, MD, Naveen Pemmaraju, MD, Tapan M. Kadia, MD, Guillermo Garcia-Manero, MD, Hagop M. Kantarjian, MD, Marina Y Konopleva, MD PhD, Courtney D. DiNardo, MD MSc

Blood (2019) 134 (Supplement_1): 567.

https://doi.org/10.1182/blood-2019-125970

Published: 2019

Journal Articles

Inhibition of PIM Kinases Targets Synthetic Vulnerabilities and Enhances Antigen Presentation in B-Cell Lymphoma

Patrizia Mondello, MD PhD MSc, Chiara Tarantelli, PhD, Luciano Cascione, PhD, Alberto Arribas, PhD, Andrea Rinaldi, Anas Younes, MD, Francesco Bertoni, MD

Blood (2019) 134 (Supplement_1): 2858.

https://doi.org/10.1182/blood-2019-125123

Published: 2019

Journal Articles

Glutaminase Inhibition Overcomes Acquired Resistance to Mitochondrial Complex I in NOTCH1-Driven T-Cell Acute Lymphoblastic Leukemias (T-ALL) Via Block of Glutamine Driven Reductive Metabolism

Blood (2019) 134 (Supplement_1): 806.

https://doi.org/10.1182/blood-2019-128930

Published: 2019

Journal Articles

Glutamine Depletion By Addicted Myeloma Cells Inhibits Osteoblastic Differentiation of Bone Marrow Mesenchymal Stromal Cells Limiting Asparagine Availability: A Possible New Mechanism for Myeloma Bone Disease

Martina Chiu, PhD, Denise Toscani, PhD, Emanuela Vicario, PhD, Roberta Andreoli, PhD, Giuseppe Taurino, MS, Valentina Marchica, MS, Paola Storti, PhD, Massimiliano Bianchi, PhD, Ovidio Bussolati, MD PhD, Nicola Giuliani

Blood (2019) 134 (Supplement_1): 4339.

https://doi.org/10.1182/blood-2019-128034

Published: 2019

Journal Articles

The Distinctive Metabolic Environment of the Bone Marrow Niche Drives Leukemia Chemoresistance

Nick van Gastel, PhD, Jessica B. Spinelli, PhD, Azeem Sharda, MS, Amir Schajnovitz, PhD, Ninib Baryawno, PhD, Catherine S Rhee, PhD, Toshihiko Oki, MD PhD, Eliane Grace, Heather J. Soled, Charles Vidoudez, PhD, Sunia A. Trauger, PhD, Marcia C. Haigis, PhD, David T. Scadden, MD

Blood (2019) 134 (Supplement_1): 3725.

https://doi.org/10.1182/blood-2019-124789

Published: 2019

Journal Articles

OPB-111077 in Combination with Decitabine and Venetoclax for the Treatment of Acute Myeloid Leukemia

Lindsay Wilde, MD, Ubaldo Martinez-Outschoorn, MD, Neil Palmisiano, MD MS, Margaret Kasner, MDMSc

Blood (2019) 134 (Supplement_1): 2597.

https://doi.org/10.1182/blood-2019-131979

Published: 2019

Journal Articles

Trial in Progress: Phase I Dose-Escalation and Dose-Expansion Trial of a Novel Glutaminase Inhibitor (CB-839 HCl) in Combination with Carfilzomib and Dexamethasone in Relapsed and/or Refractory Multiple Myeloma

Wilson I Gonsalves, MD, Srinivas Devarakonda, MD, Rachid Baz, MD, Natalia Neparidze, MD, Alex A Adjei, MD PhD, Charles Kunos, MD, Shaji K. Kumar, MD

Blood (2019) 134 (Supplement_1): 3160.

https://doi.org/10.1182/blood-2019-123399

Published: 2019

Journal Articles

Mitochondrial Complex I Inhibitor Iacs-010759 Reverses the NOTCH1-Driven Metabolic Reprogramming in T-ALL Via Blockade of Oxidative Phosphorylation: Synergy with Chemotherapy and Glutaminase Inhibition

Blood (2018) 132 (Supplement 1): 4020.

https://doi.org/10.1182/blood-2018-99-117310

Published: 2018

Journal Articles

Effect of Metabolic Reprogramming on the Biological Activity of Acute Myeloid Leukemia Cells

Tongyuan Liu, MD, Dengju Li, MD, Jianfeng Zhou, PhD

Blood (2018) 132 (Supplement 1): 5227.

https://doi.org/10.1182/blood-2018-99-115654

Published: 2018

Journal Articles

Contribution of Amino Acid Metabolism to Hematologic Malignancies

Marina Y. Konopleva, MD PhD, Philip L Lorenzi, PhD, Sanaz Ghotbaldini, Yoko Tabe, MD PhD, Tianyu Cai, PhD, Stefano Tiziani, PhD

Blood (2018) 132 (Supplement 1): SCI-10.

https://doi.org/10.1182/blood-2018-99-109469

Published: 2018

Journal Articles

T Cell Metabolism and Memory

Jeffrey C Rathmell, PhD

Blood (2018) 132 (Supplement 1): SCI-6.

https://doi.org/10.1182/blood-2018-99-109535

Published: 2018

Journal Articles

The Glutaminase Activity of L-Asparaginase Mediates Suppression of Asns Upregulation

Wai Kin Chan, PhD, Lin Tan, MS, Karine Harutyunyan, PhD, Di Du, PhD, Leona Martin, MS, Eric Yin, MS, Marina Y. Konopleva, MD PhD, John Weinstein, MD PhD, Philip L Lorenzi, PhD

Blood (2018) 132 (Supplement 1): 3959.

https://doi.org/10.1182/blood-2018-99-117818

Published: 2018

Journal Articles

Erwinia Chrysantemi-Derived L-Asparaginase Strongly Enhances Proteasome Inhibitors Activity By Deregulating Cell Metabolic Programs

Paola Minetto, MD, Debora Soncini, PhD, Fabio Guolo, MD, Samantha Ruberti, BSc, PhD, Veronica Retali, Paola Contini, Nadia Bisso, MD, Nikki Di Felice, MD, Giulia Rivoli, MD, Antonia Cagnetta, MD, Marco Gobbi, MD, Roberto Massimo Lemoli, MD, Michele Cea, MD

Blood (2018) 132 (Supplement 1): 3221.

https://doi.org/10.1182/blood-2018-99-119622

Published: 2018

Journal Articles

Glutamine-Dependence Targeting By Asparaginase Significantly Increases Anti-Myeloma Activity of Proteasome Inhibitors

Paola Minetto, MD, Debora Soncini, PhD, Antonia Cagnetta, MD, Fabio Guolo, MD, Veronica Retali, Giulia Rivoli, MD, Nadia Bisso, MD, Nikki Di Felice, MD, Maurizio Miglino, PhD, Letizia Canepa, MD, Roberto Massimo Lemoli, MD, Marco Gobbi, MD, Michele Cea

Blood (2017) 130 (Supplement 1): 1796.

https://doi.org/10.1182/blood.V130.Suppl_1.1796.1796

Published: 2017

Journal Articles

Metabolic Profiling of Adult Acute Myeloid Leukemia (AML)

Blood (2016) 128 (22): 1684.

https://doi.org/10.1182/blood.V128.22.1684.1684

Published: 2016

Journal Articles

Red Blood Cell-Encapsulation of L-Asparaginase Favorably Modulates Target Selectivity and Pharmacodynamics

Philip L Lorenzi, PhD, Thomas D Horvath, PhD, Leona A Martin, M.S., Wai Kin Chan, PhD, Di Du, PhD, David H. Hawke, PhD, John N Weinstein, MD,PhD, Kenneth J Swart, PhD, Iman El-Hariry, MD PhD

Blood (2016) 128 (22): 1266.

https://doi.org/10.1182/blood.V128.22.1266.1266

Published: 2016

Journal Articles

Glutaminase Inhibitor CB-839 Enhances Proteasome Inhibitor Sensitivity in Multiple Myeloma Cells

Ravyn M. Thompson, Leticia Reyes, Brittany Smith, Nathan G. Dolloff, PhD

Blood (2016) 128 (22): 3294.

https://doi.org/10.1182/blood.V128.22.3294.3294

Published: 2016

Journal Articles

Gls Inhibitor CB-839 Modulates Cellular Metabolism in AML and Potently Suppresses AML Cell Growth When Combined with 5-Azacitidine

Tianyu Cai, PhD, Philip L Lorenzi, PhD, Dinesh Rakheja, MD, Michael A Pontikos, Alessia Lodi, Lina Han, MD PhD, Qi Zhang, MD PhD, Helen Ma, MS, Mohamed Rahmani, PhD, Tushar Damodar Bhagat, PhD, Thomas D Horvath, PhD, Courtney D. DiNardo, MD MSCE, Steven Grant, MD, Stefano Tiziani, PhD, Amit Verma, MD, Marina Konopleva, MD PhD

Blood (2016) 128 (22): 4064.

https://doi.org/10.1182/blood.V128.22.4064.4064

Published: 2016

Journal Articles

Dependence on glutamine uptake and glutamine addiction characterize myeloma cells: a new attractive target

Blood (2016) 128 (5): 667–679.

https://doi.org/10.1182/blood-2016-01-690743

Published: 2016

Includes: Supplemental data

Journal Articles

Metabolomic, Proteomic and Genomic Profiling Identifies Biomarakers of Sensitivity to Glutaminase Inhibitor CB-839 in Multiple Myeloma

Andrew L MacKinnon, PhD, Mark Bennett, PhD, Matt Gross, B.S., Julie Janes, M.S., Weiqin Li, PhD, Mirna Rodriquez, B.S., Tracy Wang, BS, Winter Zhang, B.S., Francesco Parlati, PhD

Blood (2015) 126 (23): 1802.

https://doi.org/10.1182/blood.V126.23.1802.1802

Published: 2015

NARROW

Interim Analysis of a Phase II Study of the Glutaminase Inhibitor Telaglenastat (CB-839) in Combination with Azacitidine in Advanced Myelodysplastic Syndrome (MDS)

Inhibition of PIM Kinases Targets Synthetic Vulnerabilities and Enhances Antigen Presentation in B-Cell Lymphoma

Glutaminase Inhibition Overcomes Acquired Resistance to Mitochondrial Complex I in NOTCH1-Driven T-Cell Acute Lymphoblastic Leukemias (T-ALL) Via Block of Glutamine Driven Reductive Metabolism

Glutamine Depletion By Addicted Myeloma Cells Inhibits Osteoblastic Differentiation of Bone Marrow Mesenchymal Stromal Cells Limiting Asparagine Availability: A Possible New Mechanism for Myeloma Bone Disease

The Distinctive Metabolic Environment of the Bone Marrow Niche Drives Leukemia Chemoresistance

OPB-111077 in Combination with Decitabine and Venetoclax for the Treatment of Acute Myeloid Leukemia

Trial in Progress: Phase I Dose-Escalation and Dose-Expansion Trial of a Novel Glutaminase Inhibitor (CB-839 HCl) in Combination with Carfilzomib and Dexamethasone in Relapsed and/or Refractory Multiple Myeloma

Mitochondrial Complex I Inhibitor Iacs-010759 Reverses the NOTCH1-Driven Metabolic Reprogramming in T-ALL Via Blockade of Oxidative Phosphorylation: Synergy with Chemotherapy and Glutaminase Inhibition

Effect of Metabolic Reprogramming on the Biological Activity of Acute Myeloid Leukemia Cells

Contribution of Amino Acid Metabolism to Hematologic Malignancies

T Cell Metabolism and Memory

The Glutaminase Activity of L-Asparaginase Mediates Suppression of Asns Upregulation

Erwinia Chrysantemi-Derived L-Asparaginase Strongly Enhances Proteasome Inhibitors Activity By Deregulating Cell Metabolic Programs

Glutamine-Dependence Targeting By Asparaginase Significantly Increases Anti-Myeloma Activity of Proteasome Inhibitors

Metabolic Profiling of Adult Acute Myeloid Leukemia (AML)

Red Blood Cell-Encapsulation of L-Asparaginase Favorably Modulates Target Selectivity and Pharmacodynamics

Glutaminase Inhibitor CB-839 Enhances Proteasome Inhibitor Sensitivity in Multiple Myeloma Cells

Gls Inhibitor CB-839 Modulates Cellular Metabolism in AML and Potently Suppresses AML Cell Growth When Combined with 5-Azacitidine

Dependence on glutamine uptake and glutamine addiction characterize myeloma cells: a new attractive target

Metabolomic, Proteomic and Genomic Profiling Identifies Biomarakers of Sensitivity to Glutaminase Inhibitor CB-839 in Multiple Myeloma

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only